News
CANF
0.2650
-6.29%
-0.0178
Weekly Report: what happened at CANF last week (1208-1212)?
Weekly Report · 1d ago
Weekly Report: what happened at CANF last week (1201-1205)?
Weekly Report · 12/08 09:42
Can Fite Biofpharma Showcases Pipeline Progress in Oncology and Inflammatory Disease Drug Development
Reuters · 12/01 21:35
Weekly Report: what happened at CANF last week (1124-1128)?
Weekly Report · 12/01 09:40
Can-Fite BioPharma Showcases Advanced Drug Pipeline at Noble Capital Markets Emerging Growth Conference
Reuters · 11/26 12:00
12 Health Care Stocks Moving In Monday's After-Market Session
Benzinga · 11/24 21:05
Can-Fite BioPharma to participate in BioFIT 2025
TipRanks · 11/24 12:15
Weekly Report: what happened at CANF last week (1117-1121)?
Weekly Report · 11/24 09:43
Can-Fite BioPharma Adjusts Warrant Terms to Enhance Market Appeal
TipRanks · 11/21 22:04
Can-Fite’s CF602 Secures Patent in Brazil for Erectile Dysfunction Treatment
TipRanks · 11/20 12:27
Can-Fite BioPharma receives Notice of Allowance from Brazil for patent on CF602
TipRanks · 11/20 12:05
Can-Fite Secures Brazilian Patent for Erectile Dysfunction Drug Candidate CF602
Benzinga · 11/20 12:04
CAN-FITE’S CF602 ERECTILE DYSFUNCTION TREATMENT RECEIVES NOTICE OF PATENT ALLOWANCE IN BRAZIL
Reuters · 11/20 12:03
Can-Fite BioPharma’s CF602 Erectile Dysfunction Treatment Receives Patent Allowance in Brazil
Reuters · 11/20 12:00
Can-Fite Biopharma Is Maintained at Buy by D. Boral Capital
Dow Jones · 11/18 19:40
Can-Fite Biopharma Price Target Maintained With a $11.00/Share by D. Boral Capital
Dow Jones · 11/18 19:40
D. Boral Capital Maintains Buy on Can Fite Biofarma, Maintains $11 Price Target
Benzinga · 11/18 19:30
Morning News Wrap-Up: Tuesday’s Biggest Stock Market Stories!
TipRanks · 11/18 18:17
Nasdaq Down 1%; Medtronic Earnings Top Views
Benzinga · 11/18 17:53
Dow Falls Over 300 Points; Home Depot Posts Downbeat Earnings
Benzinga · 11/18 14:55
More
Webull provides a variety of real-time CANF stock news. You can receive the latest news about Can-Fite BioPharma Ltd. through multiple platforms. This information may help you make smarter investment decisions.
About CANF
Can Fite Biopharma Ltd is an Israel-based clinical-stage biopharmaceutical company engaged in developing orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases and erectile dysfunction. The Company co-develop formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. Its technology utilizes the Gi protein associated A3AR as a therapeutic target. A3AR is expressed in inflammatory and cancer cells, and not significantly expressed in normal cells, suggesting that the receptor could be a target for pharmacological intervention.